Tennessee · J3245

Injection, Tildrakizumab, 1 Mg in Tennessee

Tennessee Medicare Avg
$109.89
1% above national avg
National Medicare Avg
$109.29
All states combined
Billed Charge (TN)
$381.58
What providers submit
Est. Commercial (TN)
$296.80
National avg: $307.58
Est. Cash / Self-Pay (TN)
$208.47
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

92.7K
Services in TN
80
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Tennessee

Provider Medicare Services
Harmon, Krista MSN, FNP-C $110.06 8.8K
Overholser, Emily M.D. $109.91 5.7K
Cantrill, Deena $109.68 5.3K
Schneider, Michael MD $109.91 5.3K
Mills, Kristen FNP-BC $109.73 4.3K
Beck, Katherine APN-BC $110.00 3.8K
Page, Nicole NP $109.38 3.8K
Dwyer, Allie FNP $110.39 3.8K
Robinson, Rachel NP-C $110.08 3.0K
Barnett, Meredith FNP $110.29 2.2K
Schwartz, Jamie MSN, APRN, FNP-C $111.24 2.1K
Morris, Destiny FNP-C $109.32 1.9K

Tennessee Pricing in Context

In Tennessee, CPT code J3245 (Injection, Tildrakizumab, 1 Mg) carries an average Medicare payment of $109.89 — 1% above the national benchmark of $109.29. 80 providers across the state submitted claims for this procedure in 2023, performing 92.7K total services. Individual payments in TN ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Tennessee is $381.58, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Tennessee sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Drugs (Administered) procedures, the estimated commercial insurance price in Tennessee lands near $296.80, with self-pay cash prices typically around $208.47. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Injection, Tildrakizumab, 1 Mg cost in Tennessee?

The average Medicare payment for Injection, Tildrakizumab, 1 Mg in Tennessee is $109.89, which is 1% above the national average of $109.29. Providers in TN typically bill $381.58 for this procedure.

What does Injection, Tildrakizumab, 1 Mg cost with insurance in Tennessee?

With commercial insurance in Tennessee, Injection, Tildrakizumab, 1 Mg costs an estimated $296.80. Without insurance, the estimated cash price is $208.47. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Injection, Tildrakizumab, 1 Mg in Tennessee?

80 providers in Tennessee billed Medicare for Injection, Tildrakizumab, 1 Mg in 2023, performing 92.7K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Injection, Tildrakizumab, 1 Mg cheaper in Tennessee than the national average?

No — Injection, Tildrakizumab, 1 Mg costs 1% above the national average in Tennessee. The state average Medicare payment is $109.89 compared to $109.29 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial